SCHEMBL989139

SCHEMBL989139

CN1CCN(c2cnc(C(F)(F)F)c(C3=C(c4cn(C)c5ccccc45)C(=O)NC3=O)c2)CC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 1/20 0.57
PRKCB P05771 4/20 0.56
PRKCA P17252 3/20 0.56
PRKCE Q02156 3/20 0.56
PRKCD Q05655 3/20 0.56
PRKCH P24723 2/20 0.56
PRKCQ Q04759 1/20 0.56
CDK2 P24941 2/20 0.54
CCNE2 O96020 1/20 0.54
CDK4 P11802 1/20 0.54
CCND1 P24385 1/20 0.54
CCNE1 P24864 1/20 0.54
PRKCG P05129 2/20 0.52
PRKCZ Q05513 1/20 0.52
CAMK2B Q13554 1/20 0.52
CAMK2G Q13555 1/20 0.52
CAMK2D Q13557 1/20 0.52
CAMK2A Q9UQM7 1/20 0.52
GSK3B P49841 4/20 0.51
CCNT1 O60563 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL989017 0.83 PRKCA (0.66) JAK3PRKCBPRKCAPRKCEPRKCD
SCHEMBL990030 0.81 GSK3B (0.62) PRKCBPRKCAPRKCEPRKCDPRKCH
SCHEMBL3547465 0.81 CDK4 (0.60) JAK3PRKCBPRKCAPRKCEPRKCD
SCHEMBL7987757 0.80 CCNE2 (0.66) JAK3PRKCBPRKCAPRKCEPRKCD
SCHEMBL990732 0.79 PRKCA (0.57) JAK3PRKCBPRKCAPRKCEPRKCD
SCHEMBL13038942 0.76 CCNE2 (0.57) PRKCBPRKCAPRKCEPRKCDPRKCH
SCHEMBL3552786 0.75 CCNE2 (0.60) PRKCBPRKCAPRKCEPRKCDPRKCH
SCHEMBL4543351 0.74 PRKCB (0.69) PRKCBPRKCAPRKCEPRKCDPRKCH
SCHEMBL30319849 0.73 CCNE2 (1.00) PRKCACDK2CCNE2CDK4CCND1
SCHEMBL5686048 0.73 CCNE2 (1.00) PRKCACDK2CCNE2CDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2270001-A1 Indolylmaleimide derivatives as PKC inhibitors Novartis AG (CH) 2011-01-05 EP claimed
US-7648989-B2 Indolylmaleimide derivatives as PKC inhibitors NOVARTIS AG (CH) 2010-01-19 US claimed
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors NOVARTIS AG (CH) 2008-10-02 US claimed
JP-2007518731-A 2007-07-12 JP claimed
EP-1745037-A1 INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS Novartis AG (CH) 2007-01-24 EP claimed
WO-2005068455-A1 INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS NOVARTIS AG (CH) 2005-07-28 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242675-A1 Indolylmaleimide Derivatives as Pkc Inhibitors PRKCE, PRKCH, PRKCI JAK3 1488/4885PRKCB 5/4885PRKCA 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.